Author:
Patel A.,Goldstein D.A.,Tannock I.F.
Reference6 articles.
1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
2. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
3. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial;Motzer;J Clin Oncol,2015
4. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors;Patnaik;Clin Cancer Res,2015
5. Alternative dosing regimens for atezolizumab: right dose, wrong frequency;Goldstein;Cancer Chemother Pharmacol,2019
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献